Humanin Research Overview

Discovery: A Paradigm-Shifting Finding

Humanin was discovered in 2001 by Nishimoto and colleagues at the Tokyo Metropolitan Institute of Gerontology through a functional cloning screen designed to identify factors that protect neurons from Alzheimer's disease-associated cell death. cDNA from the surviving neurons of a patient with familial AD was expressed in neuronal cultures challenged with mutant APP — and one clone, encoding a 21-amino acid peptide, potently rescued cells from amyloid-induced death. When the researchers traced the gene encoding this rescue peptide, they found it within the mitochondrial genome — specifically embedded within the 16S ribosomal RNA gene.

The implications of this discovery were profound. It established for the first time that the mitochondrial genome — previously thought to encode only structural RNAs and proteins of the respiratory chain — could also produce small bioactive signalling peptides with systemic functions. Humanin became the founding member of the mitochondria-derived peptide (MDP) class, subsequently joined by MOTS-c (encoded in 12S rRNA) and SHLP 1–6 (also from 16S rRNA). The discovery opened an entirely new chapter in mitochondrial biology and peptide pharmacology.

• Sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys
• Molecular Weight: 2,703 Da (21 amino acids)
• Genetic Origin: Mitochondrial 16S rRNA gene (non-canonical ORF)
• Primary Receptors: FPRL1 / FPR2; CNTFR/WSX-1/gp130 complex; IGFBP-3
• Circulating Form: Secreted into plasma; measurable by ELISA
• Plasma Levels: Decline with age; elevated in centenarians

Receptor System and Signal Transduction

Humanin operates through multiple receptor pathways depending on tissue and cellular context — an unusual pharmacological complexity for a 21-amino acid peptide. Three distinct receptor interactions have been characterised:

FPRL1/FPR2 (Formyl Peptide Receptor-Like 1): A G-protein coupled receptor expressed on neurons, immune cells, and vascular endothelium. Humanin binding activates Gi-mediated suppression of cAMP and PI3K/AKT survival signalling — the primary mechanism for its anti-apoptotic effects in neuronal cells. This receptor mediates Humanin's neuroprotective activity against Aβ-induced toxicity.

CNTFR/WSX-1/gp130 tripartite complex: A cytokine receptor complex shared with ciliary neurotrophic factor (CNTF) and cardiotrophin-like cytokine. Humanin signalling through this complex activates JAK/STAT3 and MAPK pathways, mediating its cardiovascular and metabolic effects including insulin sensitisation and cardiomyocyte protection.

IGFBP-3 binding: Humanin binds insulin-like growth factor binding protein-3 (IGFBP-3), which normally sequesters and inactivates IGF-1. By sequestering IGFBP-3, Humanin may indirectly increase bioavailable IGF-1 — a proposed mechanism for its insulin-sensitising and anabolic effects distinct from direct receptor activation.

Research Domains

Alzheimer's NeuroprotectionPotently blocks neuronal death from mutant APP, Aβ1-42, and presenilin mutations. FPRL1-mediated AKT survival signalling. The foundational research application. Insulin SensitisationImproves glucose tolerance and insulin sensitivity in rodent diabetes models. Reduces hepatic glucose output. Studied via gp130/STAT3 signalling in liver and muscle. Cardiovascular ProtectionReduces cardiomyocyte apoptosis in ischaemia-reperfusion models. Activates CNTFR/gp130 survival signalling. Reduces infarct size in rodent MI models. Longevity BiomarkerElevated in offspring of centenarians and centenarians themselves. Correlates inversely with age-related disease burden. IGF-1/Humanin axis studied in exceptional longevity. Anti-Apoptotic SignallingInhibits Bax translocation to mitochondria. Neutralises tBid-mediated cytochrome c release. Broad anti-apoptotic activity across neuronal, cardiac, and endocrine cell types. Reproductive ResearchExpressed in testes; protects spermatogonia from chemotherapy-induced apoptosis. IGFBP-3/Humanin axis modulates gonadal function in models of gonadotoxic stress.

Alzheimer's Disease Research

Humanin's most extensively characterised application is protection against the neuronal cell death triggered by Alzheimer's disease–related insults. In cell culture models, Humanin at picomolar to nanomolar concentrations potently rescues neurons from death induced by: amyloid beta (Aβ1-42), mutant APP (V642I, K595N/M596L), mutant presenilin-1 and -2, and V337M mutant tau. This unusually broad neuroprotective spectrum against multiple AD-associated insults suggests Humanin targets a common downstream apoptotic convergence point rather than any single upstream AD pathology.

The convergence point identified is the mitochondrial apoptotic pathway — specifically the translocation of pro-apoptotic Bax from cytoplasm to mitochondria, which initiates cytochrome c release and caspase cascade activation. Humanin, via FPRL1/AKT signalling, maintains the cytoplasmic sequestration of Bax and prevents cytochrome c release even in the presence of Aβ concentrations that are otherwise uniformly lethal in neuronal cultures.

In APP transgenic mouse models of AD, chronic Humanin administration reduces amyloid plaque load, attenuates neuroinflammatory microglial activation, and preserves spatial memory in Morris water maze and fear conditioning paradigms. The therapeutic window — the dose range between neuroprotective efficacy and any adverse effect — is broad in rodent models, with no reported toxicity at 100-fold the effective dose.

Insulin Sensitisation and Metabolic Research

Humanin's metabolic effects represent a research dimension entirely distinct from its neuroprotective applications. In high-fat diet–induced diabetic mice, Humanin administration (intraperitoneal or subcutaneous) significantly improves insulin tolerance testing and glucose tolerance testing outcomes, reduces fasting hyperglycaemia, and decreases hepatic glucose production. The mechanism involves Humanin activation of the gp130/JAK2/STAT3 pathway in hepatocytes, which reduces gluconeogenic gene expression (PEPCK, G6Pase) — the same pathway activated by IL-6 and CNTF in hepatic glucose regulation.

Notably, Humanin's insulin-sensitising effects appear to be enhanced in states of IGF-1 deficiency or low bioavailability — consistent with its IGFBP-3 binding activity indirectly increasing IGF-1 bioavailability. This creates a potential research intersection between Humanin, the IGF-1/IGFBP axis, and metabolic disease that has not been fully explored.

Centenarian Research and Longevity Biology

Among the most remarkable findings in Humanin research are its associations with exceptional human longevity. Studies by Cohen and colleagues at USC have documented that: (1) Humanin plasma levels decline with normal aging, (2) children of centenarians have significantly higher Humanin levels than age-matched controls without centenarian parents, and (3) centenarians themselves have Humanin levels comparable to individuals decades younger. These findings are consistent with Humanin functioning as a mitochondrial stress signal that reflects mitochondrial reserve capacity — higher Humanin indicating better-preserved mitochondrial health and stress resilience.

HN-G: The Potency-Enhanced Analogue > > Several Humanin analogues have been developed with enhanced potency. HNG (S14G-Humanin) — where serine at position 14 is substituted with glycine — is approximately 1,000-fold more potent than native Humanin in neuronal protection assays while retaining the same receptor binding profile. HNG is now the standard research tool in most contemporary Humanin studies, as it allows demonstration of biological effects at lower doses and shorter treatment durations. When evaluating Humanin research literature, it is important to note whether experiments used native Humanin or HNG, as dose requirements differ substantially.

Cardiovascular and Reproductive Research

Humanin's cardiovascular research parallels its neuroprotective mechanism: by preventing cardiomyocyte apoptosis through the same Bax/cytochrome c pathway inhibition, it reduces infarct size in cardiac ischaemia-reperfusion models. CNTFR/gp130 activation in cardiomyocytes provides additional cardioprotection through PI3K/AKT and ERK survival signalling. In reproductive biology, Humanin expressed in spermatogonia protects male germ cells from chemotherapy-induced apoptosis — a finding with potential implications for fertility preservation research in oncology contexts.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Humanin and its analogues are not approved by the FDA for any human therapeutic use. All evidence pertains to preclinical research models and observational human studies. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ." *Proc Natl Acad Sci USA*. 2001;98(11):6336–6341.

1. Muzumdar RH, et al. "Humanin: a novel central regulator of peripheral insulin action." *PLoS One*. 2009;4(7):e6334.

1. Cohen P, et al. "Elevated levels of IGF-1 binding proteins in subjects with centenarian parents." *J Gerontol A Biol Sci Med Sci*. 2006;61(2):105–108.

1. Guo B, et al. "Humanin peptide suppresses apoptosis by interfering with Bax activation." *Nature*. 2003;423(6938):456–461.

1. Lee C, et al. "MOTS-c: A mitochondrial-encoded regulator of the metabolic stress response." *Cell Metab*. 2015;21(3):443–454.

1. Kuliawat R, et al. "Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the beta cell." *FASEB J*. 2013;27(12):4890–4898.